Risultati della ricerca - Jason J. Luke

Raffina i risultati
  1. 1
    Considering adjuvant therapy for stage II melanoma

    Considering adjuvant therapy for stage II melanoma di Andrew Poklepovic, Jason J. Luke

    Pubblicazione 2019
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response

    Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response di Christopher Garris, Jason J. Luke

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

    PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma di Jason J. Luke, Patrick A. Ott

    Pubblicazione 2015
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Chemotherapy in the management of advanced cutaneous malignant melanoma

    Chemotherapy in the management of advanced cutaneous malignant melanoma di Jason J. Luke, Gary K. Schwartz

    Pubblicazione 2013
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

    Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma di Jason J. Luke, F. Stephen Hodi

    Pubblicazione 2013
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

    Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis di Brian Labadie, Riyue Bao, Jason J. Luke

    Pubblicazione 2018
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    <p>Toll-Like Receptor 9 Agonists in Cancer</p>

    <p>Toll-Like Receptor 9 Agonists in Cancer</p> di Lilit Karapetyan, Jason J. Luke, Diwakar Davar

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

    Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types di Riyue Bao, Daniel Stapor, Jason J. Luke

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

    Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy di Claudia Trojaniello, Jason J. Luke, Paolo A. Ascierto

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    Targeting Cbl-b in cancer immunotherapy

    Targeting Cbl-b in cancer immunotherapy di Ryan C. Augustin, Riyue Bao, Jason J. Luke

    Pubblicazione 2023
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

    High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery di Jessica Zielinski, Jason J. Luke, Silvia Guglietta, Carsten Krieg

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  12. 12
    T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

    T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection di Jonathan Trujillo, Randy F. Sweis, Riyue Bao, Jason J. Luke

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    <i>ACE2</i>and<i>TMPRSS2</i>expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

    <i>ACE2</i>and<i>TMPRSS2</i>expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19 di Riyue Bao, Kyle M. Hernandez, Lei Huang, Jason J. Luke

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    STING Agonists as Cancer Therapeutics

    STING Agonists as Cancer Therapeutics di Afsaneh Amouzegar, Manoj Chelvanambi, J Filderman, Walter J. Storkus, Jason J. Luke

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  15. 15
    WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

    WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers di Jason J. Luke, Riyue Bao, Randy F. Sweis, Stefani Spranger, Thomas F. Gajewski

    Pubblicazione 2019
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    STING pathway agonism as a cancer therapeutic

    STING pathway agonism as a cancer therapeutic di Blake Flood, Emily F. Higgs, Shuyin Li, Jason J. Luke, Thomas F. Gajewski

    Pubblicazione 2019
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  17. 17
    Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

    Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies di Christopher C. Frohne, Ernesto M. Llano, Ashley Perkovic, Russell D. Cohen, Jason J. Luke

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors

    Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors di Shalin Shah, James E. Ward, Riyue Bao, Curtis R. Hall, Bruce Brockstein, Jason J. Luke

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy

    Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy di Ryan C. Augustin, Robert D. Leone, Aung Naing, Lawrence Fong, Riyue Bao, Jason J. Luke

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  20. 20
    The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

    The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients di Vyara Matson, Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria‐Luisa Alegre, Jason J. Luke, Thomas F. Gajewski

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: